OUR MISSION:
To partner with healthcare providers, payers, patients and advocacy groups to eradicate colorectal cancer.

Learn More

Cologuard: the first and only FDA approved stool DNA noninvasive colorectal cancer screening test.*

Learn More about Cologuard
*For average risk individuals only. Click the link above and talk to your doctor to see if Cologuard is right for you.

Latest News

Exact Sciences Highlights Cologuard's® Positive Launch Trajectory in Second Quarter 2015

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS) today announced its business and financial results for the second quarter of 2015, and showed continued strong performance with more than 21,000 completed Cologuard tests for the quarter, up more than 90 percent from the first quarter, which resulted in $8.1 million in revenue. Additionally, the cumulative number of ordering...Read more

Exact Sciences Provides Update on Strong Launch Trajectory of Cologuard®

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS) today announced that it expects to end the second quarter of 2015 with approximately 21,000 completed Cologuard tests. More than 13,800 physicians ordered at least one Cologuard test since the October 2014 launch and the patient compliance rate for Cologuard rose to 73 percent. The company anticipates completing approximately...Read more

Be Seen, Get Screened
1 in 3 is not getting screened for colon cancer. Let's bring everyone out of hiding and in to get screened. Join us on Be Seen, Get Screened to help spread the word.

Exact Sciences Laboratories is dedicated to delivering the most accurate results and providing physicians and patients with world-class service.

Go To ExactLabs.com

FOR OUR INVESTORS

View updates on upcoming conference appearances, company news, financial reports and more.

Learn More